Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy

Starting soon · Phase 1/Phase 2

Conditions studied: Urinary Bladder, Overactive, Spinal Cord Injury

In brief

The aim of this study is to continue following participants who have received EG110A during five years to know how it is tolerated in humans, any side-effects it may cause and what might be an effective dose over five years. All participants who have received at least one dose/injection of EG110A in a previous clinical study of EG110A will be asked to roll-over to this long-term follow-up study upon either early discontinuation from, or completion of, that study.

Key facts

Study ID

NCT07227285

Run by

Cyllene Therapeutics

People needed

16

Starts

2026-04-01

Expected to finish

2031-04-01

Last updated by the study team

2025-11-12

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All participants who received at least one dose/injection of EG110A in Study EG110A-001-01 and have prematurely discontinued or completed that study.

You may not qualify if…

• Participant plans to participate in another investigational gene therapy study
• Participant has an uncontrolled intercurrent illness, any disorder, or current substance abuse that would limit compliance with study requirements in the opinion of the investigator

Where it is running

• Rancho Los Amigos National Rehabilitation Center — Downey, California, United States
• University of Michigan Rogel Cancer Center — Ann Arbor, Michigan, United States
• Sidney Kimmel Medical College — Philadelphia, Pennsylvania, United States
• UTHealth Houston / TIRR Memorial Hermann — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.